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mediciNe & HealtH/RHode iSlaNd
the world health organIzatIon haS 
identified antimicrobial resistance as one 
of the top three greatest threats to human 
health. Today, infections by methicillin-
resistant Staphylococcus aureus (MRSA) 
account for more deaths in US hospitals 
than both tuberculosis and HIV/AIDS 
combined.1 More than 60% of staph in-
fections in intensive care units are due to 
drug resistant strains,1 and it is common 
to encounter those that lack sensitivity 
to multiple classes of drugs.2 In addition, 
pathogenic Escherichia coli and Klebsiella 
pneumoniae are increasingly found to 
produce an extended spectrum of enzymes 
that significantly decrease drug options 
for treating infections and often leave 
patients with limited to no antimicrobial 
treatment options. Regrettably, antimi-
crobial research and development is not 
keeping pace with rising drug resistance.3 
There are currently no novel drugs in 
late stage development for the treatment 
of multidrug-resistant Gram-negative 
pathogens.
Going deep for drug discovery: an ocean to Bedside 
Approach to Explore Sub-Seafloor Microbes for the 
Next Generation of antibiotics
Stephanie Forschner-Dancause, PhD, Kerry LaPlante, PharmD, David C. Smith, PhD, and David C. Rowley, PhD
This leads scientists and clinicians to 
ask, “Where will the next generation of anti-
biotics come from?” A crucial component in 
drug discovery methods should continue 
to be the proven strategy of screening mol-
ecules from nature. Most of our clinically 
important antibiotics such as penicillins, 
tetracyclines, and macrolides have been 
discovered through the study of secondary 
metabolites produced by terrestrial micro-
organisms. In recent years, however, the 
repeated cultivation of the same microbial 
species from terrestrial soils has resulted 
in disappointing outcomes.4 Frontier 
resources for the discovery of novel mol-
ecules are therefore critical to meet the 
genuine need for new antibiotics.
explorIng the oCean
More than 70% of the earth’s surface is 
comprised of ocean, and about 60% of the 
ocean floor is covered by water more than 
2000 meters deep. Due to obvious technical 
challenges, sediments underlying the deep 
ocean remain one of the least explored 
environments for microbiology. At all 
taxonomic levels, there is more diversity of 
life in the deep sea than initially imagined.5 
Such biodiversity leads one to believe that 
the deep sea represents the next frontier in 
the search for exploitable biology.6 
CollaboratIon
A new collaboration was formed by 
URI scientists to capitalize on the potential 
to discover new antibiotics produced by 
microbes from deep oceanic sediments. 
This interdisciplinary collaboration taps 
existing strengths in the fields of deep 
ocean microbiology (Smith lab, Graduate 
School of Oceanography), marine-based 
antibiotic drug discovery (Rowley Lab, 
College of Pharmacy), and evaluation 
(LaPlante Lab, VA Medical Center). It 
further leverages the opportunity to access 
deep oceanic sediments collected during 
expeditions conducted by the Integrated 
Ocean Drilling Program (IODP). This 
scientific ocean drilling program, sup-
ported by 25 countries, and its predeces-
sors the Deep Sea Drilling 
Project (DSDP) and the 
Ocean Drilling Program 
(ODP), has retrieved sedi-
ment core samples from 
around the globe since 
1968. Exploration of the 
subseafloor microbial com-
munity began in earnest in 
the late 1990s.
In 2010, David C. 
Smith participated in the 
Integrated Ocean Drill-
ing Program (DSDP 
IODP) Expedition 329 
to the South Pacific Gyre 
(SPG)—one of Earth’s 
five major rotating ocean 
currents—where they 
cored the sediment stack 
underlying average ocean 
depths of 5,057 meters.7 It 
possesses the lowest burial 
rates for organic matter 
Figure 1. Discovery of antibiotic compounds from subsurface sediments of the South Pacific Gyre. Clockwise 
from top left: Bathymetric map of the South Pacific Gyre with black dots representing sampling sites, large scale 
static cultivations of a fungal strain isolated from SPG sediments, cross section example of subsurface sediment 
cores from which the SPG culture collection was isolated, SPG strains were investigated for antibiotic activity 
using disc diffusion assays.  
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in the ocean8 and has been described as 
the Earth’s largest oceanic desert. The 
sedimentary microbial community has ex-
tremely low biomass and metabolic activ-
ity and is predicted to be unlike any others 
of the same depth previously studied by 
drilling programs.9  In total, 105 samples 
were collected from sediment cores within 
the gyre ranging in depth from 1.3 to 75.3 
meters below the seafloor (mbsf ) and an 
additional 27 subcores ranging in depth 
from 1.4 to 126.9 mbsf were collected 
from the control site. (Figure 1)
The Rowley group has isolated 150 
bacterial and 120 fungal strains from these 
deep ocean sediments. Taxonomic identifi-
cation of the bacteria has been undertaken, 
and many strains identified to date are 
related to genera and groups recognized 
to be productive for drug discovery. When 
grown at atmospheric pressure, room tem-
perature and on standard marine media, 
a remarkable 60% of bacterial and over 
80% of fungal isolates assayed to date from 
the SPG subsurface sediments produce 
molecules possessing antibacterial proper-
ties against human pathogens, including 
methicillin-resistant Staphylococcus aureus, 
Pseudomonas aeruginosa PA01, and Acine-
tobacter baumannii. 
The next step in this collaborative in-
vestigation involves the identification of the 
exact antibiotics being produced by these 
microorganisms. Many of the antibiotic 
producers have been cultured in multi-liter 
scale, and chemical investigations of their 
bioactive compounds are underway. Once 
the antibiotic agents have been purified and 
the structures have been determined, novel 
agents will be tested for their growth inhibi-
tory activities against an array of clinically 
important pathogens at LaPlante’s labora-
tory located at the Providence Veterans 
Affairs Medical Center.10, 11
There are obvious technical chal-
lenges to accessing sediments in the 
deepest regions of the oceans and further 
difficulties arise in attempting to replicate 
the extreme environmental conditions 
of the deep ocean. For example, these 
microbes are adapted to high pressure, 
low temperature, and low organic content 
environments. It is unknown how these 
parameters may influence the growth of 
the microorganisms or whether they are 
critical for the expression of genes lead-
ing to antibiotic production. While we 
can duplicate such conditions in the lab, 
such cultivations are not conducive to the 
scale and throughput necessary for drug 
discovery efforts. Nevertheless, a subset of 
the deep-sea microbiota can be cultivated 
under normal laboratory conditions, and 
these have shown promise for the produc-
tion of bioactive molecules. 
The South Pacific Gyre is just one 
of five major gyre systems depleted of 
nutrients year round. The promising 
antibacterial activities of microbes from 
the SPG may provide insight into the 
biomedical potential of similar sedi-
mentary environments underlying other 
regions of open ocean. Clearly, the deep 
oceanic subsurface ecosystem should not 
be overlooked for the discovery of bioac-
tive natural products.
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